Net Income

A new alliance explores how inanimate microbes, or postbiotics, could become a novel weapon in oncology, starting with breast cancer research.

For those with severe PTSD and depression, hope is scarce. Biotech firm Compass Pathways is pioneering a psilocybin treatment that could change everything.

The platform's 2025 report reveals more than just charity; it's a real-time indicator of economic distress, disaster response, and tech-driven mutual aid.

Reborn Coffee touts a tech-driven global expansion, but a looming Nasdaq delisting and deep financial losses paint a much more complicated picture.

As restaurants face economic headwinds, a new AI platform is empowering servers, enhancing guest experience, and promising to double bottom-line profits.

A routine regulatory filing reveals Sintana Energy's major M&A play. We decode the signals, the Challenger deal, and what it means for its oil future.

A massive 320 MWh battery project in Belgium reveals how strategic investments in energy storage are becoming the ultimate luxury: grid stability and sustainability.

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?

Imviva Biotech's 'off-the-shelf' cell therapies could make life-saving treatments faster and more accessible. But what does this mean for patients?

With its AI & Autonomy Day, Rivian is betting its future on software. Investors are watching to see if its tech can deliver a true competitive edge.

Facing an OSC probe and audit delays, the legal tech firm is now seeking court relief, raising red flags for investors about its governance and finances.

Toro's acquisition of Tornado isn't just about new machinery; it's a calculated move to capture the booming, safety-critical underground excavation market.

Imviva Biotech's 'ready-to-use' CAR-T therapy shows breakthrough results, offering new hope and eliminating life-threatening waits for leukemia patients.

Global Ship Lease's steady dividend is more than investor news; it reveals deep insights into containership market health and strategic resilience.

Broadway star Morgan Dudley returns to the tech platform that discovered her, a high-stakes move for Stargaze's bid to reshape talent discovery.

Following a major clinical trial win, Kymera Therapeutics seeks $500M. We break down the high-stakes strategy behind funding a new era of medicine.

A junior miner's historic regulatory win in Oregon could set a new precedent for resource development, balancing economic promise with environmental rigor.

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.

Protara Therapeutics secured a $75M offering to advance its promising cancer drug, TARA-002, signaling renewed investor confidence in biotech innovation.

Global X's Bitcoin ETFs promise hefty semi-monthly payouts. But is this crypto-generated income a golden opportunity or a high-stakes volatility gamble?